---
title: 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
nct_id: NCT02519049
overall_status: COMPLETED
sponsor: Istituto Clinico Humanitas
study_type: OBSERVATIONAL
primary_condition: Mesothelioma, Malignant
countries: Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02519049.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02519049"
ct_last_update_post_date: 2020-10-01
last_seen_at: "2026-05-12T07:30:40.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)

**Official Title:** Diagnostic and Prognostic Role of 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) and Candidate to Pleurodesis

**NCT ID:** [NCT02519049](https://clinicaltrials.gov/study/NCT02519049)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Istituto Clinico Humanitas
- **Conditions:** Mesothelioma, Malignant
- **Start Date:** 2014-09
- **Completion Date:** 2018-12
- **CT.gov Last Update:** 2020-10-01

## Brief Summary

Prospective exploratory study specifically investigating the role of 11C-Methionine PET/CT imaging in patients affected by Malignant Pleural Mesothelioma (MPM) and candidate to pleurodesis.

## Detailed Description

This is a single-center, open-label study, lasting 36 months including an estimated period of 24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at the end of three cycles of chemotherapy.

A minimum number of 20 patients will be considered for the analysis.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* patients with an histological diagnosis of MPM eligible for pleurodesis and scheduled to undergo platinum- and pemetrexed-based chemotherapy.
* obtained informed consent

Exclusion Criteria:

* patients age \<18 years
* pregnancy or breast-feeding;
* patients affected by other malignancies within the last 3 years;
```

## Interventions

- **No intervention** (OTHER) — This is an observational study

## Primary Outcomes

- **Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing talc pleurodesis** _(time frame: Change from Baseline in SUVmax up to 1 week after talc pleurodesis.)_

## Locations (1)

- Istituto Clinico Humanitas, Rozzano, Milano, Italy

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.istituto clinico humanitas|rozzano|milano|italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02519049.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02519049*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*